A single line often inverts meaning once you see what it
answers, so neighbouring messages are always shown.
-
RML, again, I'd have to look at the MTA agreement that would tell me what was in it. We would have to pull it from the MTA. I can tell you that during the pandemic we did hundreds of MTA agreements with research institutions in the United States. If you ask me if I can remember this one directly, I can't, because if I had a person in my lab who I would say, "Take care of this MTA agreement," and they would do it.
-
Is it typical that the transmittal fee would be zero? I just don't know.
-
It depends on how much money I would have.
-
Okay. Like what does that range sometimes look like?
-
2026-04-10 09:00
Ralph S. Baric
Whatever the shipping cost are. DC.Scheduling@LexitasLegal.com
-
Okay. And how much are shipping costs?
-
You know, I haven't shipped anything. I have somebody else I have to do it. We have a person who's trained as a shipper, and they take care of it.
-
Okay. I want to go back to the DARPA question on PREEMPT. I'll show you this email, and I don't have another copy of it right now. But it is dated March 7, 2019. It's from Vineet Menarchery, and you have a couple of other folks on here from Autonomous Therapeutics. [Exhibit No. 3 shown.]
-
It says, "Ralph, I've been working on a DARPA proposal with Autonomous Therapeutics on MERS-CoV with a quick turnaround. They're funded for another DARPA project to generate therapeutic interfering particles, and are looking to apply their approach for MERS on this specific supplement call. We have been chatting for a few weeks, and they are interested in both in vitro and in vivo experiments with their MERS-CoV targeted TIPs. I am currently planning to work with them on the in vitro side, but suggest they talk directly to you about the DPPR 288/330 model."